Sabon binciken asibiti na Cleveland ya nuna a karo na farko cewa ibrutinib da aka yarda da shi na FDA (ibrutinib) na kwayar cutar lymphoma da leukemia na iya taimakawa wajen kula da cututtukan kwakwalwa da suka fi saurin mutuwa, kuma mai yiwuwa wata rana a yi amfani da marasa lafiya tare da glioblastoma Kuma inganta ƙimar rayuwa.
Dangane da rahoton Associationungiyar Twararrun Brawararrun Brawararrun Americanwararrun Americanwararrun Americanwararru ta Amurka, ƙimar rayuwar glioblastoma ba ta da yawa, kuma matsakaiciyar rayuwar marasa lafiya da ke karɓar daidaitaccen magani bai wuce watanni 15 ba. Glioblastoma shine mafi yawan cutar ƙwaƙwalwar ƙwaƙwalwar ƙwaƙwalwar ajiya kuma tana da matukar juriya ga jiyya na yanzu. Akwai buƙatar gaggawa don wadata waɗannan marasa lafiya da sababbin magunguna da wuri-wuri.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain ciwan kansa in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
